Mission Health, North Carolina Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2006
NCT00331188
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Alternative names

Fullerton Genetics Center-Mission, St. Joseph's Hospital | Mission Hospital | Mission Hospitals, Inc. - Asheville, NC

Active Ingredients

Drugs in Phase 3 Trials (1)

vapreotidum (1 trial)

Drugs in Other Trials (2)

agalsidase alfa (Replagal) (1 trial)

azithromycin (zithromax) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Esophageal and Gastric Varices (Phase 3)

Hemorrhage (Phase 3)

Hypertension (Phase 3)

Hypertension, Portal (Phase 3)

Varicose Veins (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3